Use of Site-Specific Mutagenesis and Monoclonal Antibodies to Map Regions of CD46 That Interact with Measles Virus H Protein  by Hsu, Eric C. et al.
i
t
c
s
v
p
C
v
t
g
t
1
n
c
p
p
t
2
Virology 258, 314–326 (1999)
Article ID viro.1999.9712, available online at http://www.idealibrary.com on
0
C
AUse of Site-Specific Mutagenesis and Monoclonal Antibodies to Map Regions
of CD46 That Interact with Measles Virus H Protein
Eric C. Hsu,*,† Sarah Sabatinos,*,† Flip J. Hoedemaeker,*,‡ David R. Rose,*,‡ and Christopher D. Richardson*,†,‡,1
*Department of Medical Biophysics, University of Toronto, 610 University Avenue, Toronto, Ontario, Canada M5G 2M9; †Amgen Research Institute,
620 University Avenue, Suite 706, Toronto, Ontario, Canada M5G 2C1; and ‡Ontario Cancer Institute, Division of Molecular
and Structural Biology, 610 University Avenue, Toronto, Ontario, Canada M5G 2M9
Received November 24, 1998; returned to author for revision February 1, 1999; accepted March 16, 1999
Researchers at our laboratory have been dissecting the binding domains of the receptor for the Edmonston laboratory
strain of measles virus (CD46) through site-specific mutagenesis. We initially substituted most of the hydrophilic amino acids
in the two external short consensus regions (SCRI and SCRII) of CD46 with the amino acid alanine [Hsu et al. (1997) J. Virol.
71:6144–6154] and found that the glutamic-arginine residues at positions 58 and 59 were particularly sensitive to change.
Here we consider the roles of hydrophobic amino acids in the binding between measles virus H protein and CD46.
Hydrophobic amino acids in the SCRI and SCRII domains of CD46 were systematically replaced with serine. The effects of
these changes were monitored through the interaction of Sf9 insect cells expressing the H protein and mouse OST-7 cells
synthesizing the mutant CD46 molecules. Binding was quantified through a colorimetric assay for b-galactosidase that was
also produced by the insect cells. Our results indicate that E45, Y54, 58E/R59, Y68, F69, Y101, I102, R103, D104, and Y117
seem to be critical residues for the binding of CD46 to measles virus H protein. The hydrophilic amino acid R59 in SCR1 and
hydrophobic residues Y101, I102, and Y117 in SCR2 seem to be especially important for interaction between H protein and
CD46. In addition, we mapped the antigenic epitopes of five monoclonal antibodies that are known to inhibit the binding
between H protein and CD46. Three of these antibodies recognized regions in SCR1, and two reacted with amino acids in
SCR2. For the most part, the determinants recognized by the monoclonal antibody corresponded to the amino acids that were
most sensitive to change in the binding process. The SCR1 and SCR2 domains of CD46 were modeled from an analogous
region in another complement regulatory protein, factor H, whose three-dimensional structure has been previously reported.
Amino acids implicated in binding seem to lie on one planar face of the SCR1 and SCR2 domains. These studies serve as
a prelude to understanding the structural interactions that occur between CD46 and the measles virus H protein. © 1999
Academic Pressb
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Measles virus infects about 44 million individuals and
s responsible for 1.5 million deaths each year. It is still
he number 1 infectious killer of children in developing
ountries (Clements and Cutts, 1995; Weiss,1992). De-
pite the success of immunization with an attenuated
iral vaccine, numerous measles outbreaks are still re-
orted in both Europe and North America (Clements and
utts, 1995). Measles virus is a member of the Morbilli-
irus genus, a subgroup of the paramyxovirus family, and
he Edmonston isolate of measles has been used to
enerate the attenuated vaccines that are widely used
oday (Enders, 1962; Hilleman et al.,1968; Rota et al.,
992). It is an enveloped virus with a single-stranded
egative RNA genome encoding six gene products: nu-
leocapsid protein (N) for viral RNA protection; matrix
rotein (M), which mediates virion assembly; phospho-
rotein (P) and large polymerase protein (L) for viral
ranscription and replication; fusion protein (F) for mem-
1 To whom reprint requests should be addressed. Fax: (416) 204-
278. E-mail: crichard@amgen.com.042-6822/99 $30.00
opyright © 1999 by Academic Press
ll rights of reproduction in any form reserved.
314rane fusion and penetration of the host cell membrane;
nd hemagglutinin (H) for attachment to the host cell
Do¨rig et al., 1994; Gerlier et al., 1995).
Membrane cofactor protein (MCP) or CD46 was pre-
iously identified as the host cell receptor for the Edmon-
ton laboratory strain of measles virus by two indepen-
ent groups (Do¨rig et al., 1993; Naniche et al., 1993).
D46 is a member of the regulators of complement
ctivation (RCA) family of proteins, and its gene is lo-
ated on human chromosome 1 (Liszewski et al., 1991;
iszewski and Atkinson, 1992). Complement regulators
uch as CD46 (MCP) and decay accelerating factor
DAF) interfere with the formation of the complement
ttack complex on the membrane of normal cells and
revent deregulated complement cell lysis of the host
ell. Therefore, CD46 plays a critical role in protecting
ninfected self-tissue from complement-mediated dam-
ge. The gene coding for CD46 consists of 14 exons and
3 introns and spans more than 43 kb of genomic DNA
Liszewski and Atkinson, 1992). It is a type I membrane
lycoprotein and possesses a 34-amino-acid signal pep-
ide at its amino-terminus, which is subsequently re-
oved during post-translational modification in the en-
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315INTERACTION OF CD46 AND MEASLES VIRUSoplasmic reticulum. The extracellular portion of the pro-
ein consists of four domains or short consensus regions
SCR I–IV) that characterize RCA proteins, followed by a
er/Thr/Pro-rich sequence (STP) situated just above the
embrane. In addition, CD46 has a hydrophobic trans-
embrane domain and a cytoplasmic C-terminal tail
pecified by either exon 13 or exon 14. N-glycosylation
ccurs on SCR I, II, and IV, whereas the STP region
ontains O-glycosylation sites. Differential glycosylation
nd alternative splicing of the STP region and cytoplas-
ic tails give rise to different isoforms of CD46 with
olecular masses of 57–67 kDa.
In recent years, the interaction between CD46 and
easles virus H protein has been studied extensively.
or example, monoclonal antibodies directed against
CRI or SCRII are capable of blocking viral infections in
ulture (Buchholz et al., 1997; Hsu et al., 1997; Iwata et al.,
995; Manchester et al., 1994; Seya et al., 1995). In
ddition, CD46 deletion mutants and recombinant chi-
eric molecules composed of CD46 and DAF or CD46
nd CD4 revealed that both the SCRI and SCRII domains
f CD46 were required for binding to measles virus
Buchholz et al., 1996; Hsu et al., 1997; Iwata et al., 1995;
anchester et al., 1994). Elimination of the N-linked gly-
osylation sites by mutagenesis proved that only the
arbohydrate associated with SCRII is important for virus
inding (Hsu et al., 1997; Maisner et al., 1995; Maisner al.
996). Specific regions of the SCRI and SCRII domains
ave also been implicated in binding by different groups,
ncluding ours, using either inhibitory peptides in viral
nfectivity assays or site-specific mutants in binding as-
ays (Buchholz et al., 1997; Hsu et al., 1997; Manchester
t al., 1997). In a previous publication, we demonstrated
hat a number of hydrophilic residues in CD46, including
E36/37, E45, ER58/59, and RD103/104, appeared to be
mportant for binding to the measles virus H protein (Hsu
t al., 1997). Our laboratory recently demonstrated that a
utation at position 481 of the measles virus (Edmon-
ton) hemagglutinin protein, from tyrosine (Y) to aspara-
ine (N), completely abolished binding with CD46 (Hsu et
l., 1998). Thus it appeared that hydrophobic interaction
ay also be important for binding between measles H
rotein and CD46. Therefore we proposed to systemati-
ally replace hydrophobic residues located in SCRI and
CRII domains of CD46 with the neutral amino acid
erine and to study the effect of these mutations with
espect to measles H protein–CD46 interaction. In this
ommunication, we identified hydrophobic residues that
re important for this interaction by using a binding
ssay that was previously developed in our laboratory
Hsu et al., 1997). In addition, monoclonal antibodies
irected against SCRI or SCRII domains of CD46 that
nhibited binding to H mapped near the regions where
mino acid substitutions produced the most deleterious
ffects.RESULTS
onfirmation of mutant CD46 expression by
luorescence cytometry and immunoblot analysis
Mutation of a single hydrophobic residue (Y481) in the
emagglutinin protein from the Edmonston strain of mea-
les virus appeared to abolish binding to CD46 (Hsu et
l., 1998). This observation suggests that the hydropho-
ic interactions may play a critical role in the contact
etween these two proteins. With this hypothesis in
ind, we systematically replaced each of the hydropho-
ic residues in the SCRI and II domains of CD46 with the
eutral amino acid serine and expressed these mutant
D46 molecules in mouse OST-7 cells by using recom-
inant vaccinia viruses (Fig. 1A). The surface expression
f all the CD46 mutant molecules was quantified by
luorescence cytometry (Fig. 1B), and the expression of
D46 mutants in mouse OST-7 cells was confirmed by
mmunoblot analysis (Fig. 1C). Analysis of mutant CD46
xpression and binding assays were performed 10 h
fter the OST-7 cells were infected with recombinant
accinia viruses. This ensured that the CD46 target cells
ere intact and that receptor surface expression was
airly close to physiological levels. The reactivity of the
ifferent monoclonal antibodies with the mutagenized
ortions of CD46 was compared with reactivity with the
ild-type molecule. Fluorescence from a standard mono-
lonal (either J4/48 or 122-2) reacting with the non-
utagenized SCR was first normalized to the same level
f fluorescence as from wild-type CD46. In most cases,
on-normalized values were already within 10% of each
ther. The obvious exception was when the mutation
ffected surface expression of CD46. After normalization,
he signal due to a specific monoclonal antibody reacting
ith the mutagenized SCR was compared with that from
he wild-type SCR and expressed as a percentage. Sim-
lar levels of recombinant CD46 were present on the cell
urfaces of mouse OST-7 cells expressing most of the
D46 mutants. Mean fluorescence values had a statis-
ical error of 615%; however, CD46 molecules containing
he mutations Y62S and W86S were not exposed on the
ell surface (Tables 1 and 2), even though immunoblot
nalysis showed that these proteins were synthesized
ithin the cell. We suspected that these mutations dis-
upted the folding of CD46 during post-translational pro-
essing and prevented the export of this protein to the
ell surface.
inding assays between mutant CD46 molecules and
he measles virus H protein
We previously developed a binding assay that mea-
ured the interaction between CD46 molecules ex-
ressed in mouse fibroblasts and Sf9 insect cells ex-
ressing both the measles virus H protein and b-galac-
osidase (Hsu et al., 1997; Hsu et al., 1998). Mutated
orms of CD46 were expressed in mouse OST-7 cells
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316 HSU ET AL.FIG. 1. Site-specific mutations were introduced into the SCRI and SCRII domains to evaluate the importance of hydrophobic interactions during
inding of the measles virus H protein (Edmonston strain) to CD46. (A) The amino acid sequence of CD46 is depicted, with SCRI and SCRII domains
eparated, demonstrating the individual hydrophobic residues that were mutated to serine (S). (B) Binding of mutated CD46 molecules to monoclonal
ntibodies was assessed by fluorescence cytometry to demonstrate cell surface expression of the various mutant proteins and to map the reactivity
f various monoclonal antibodies to antigenic epitopes. Suspended OST-7 cells expressing mutated CD46 molecules were incubated with the
ppropriate monoclonal antibody (J4/48, E4.3, B97, M75, or 122-2), and binding was detected with FITC-labeled goat anti-mouse IgG using a Becton
ickinson analyzer equipped with a 15-mW argon laser at 488 nm. The data were collected and analyzed using CellQuest software. Cell counts are
ndicated on the y axis, and the logarithm of the fluorescence intensity is represented on the x axis. These representative plots depict reactivity of
CRI-specific (B97 and J4/48) and SCRII-specific (M75 and 122-2) monoclonal antibodies to wild-type CD46 and mutant CD46 molecules (Y70S and
133). The positive and negative controls for antibody binding are CD46 wild type (WT) and nonimmune IgG1, respectively. Fluorescence from a
tandard monoclonal (either J4/48 or 122-2) reacting with the nonmutagenized SCR was first normalized to the same level as that from wild-type CD46.
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317INTERACTION OF CD46 AND MEASLES VIRUSsing vaccinia virus expression vectors, and Sf9 insect
ells were infected for 48 h with recombinant baculovi-
uses derived with the vector with the BlueBac II vector,
hich expressed Edmonston H protein in addition to
-galactosidase. Binding assays between infected in-
ect cells and mouse cells were performed at 37°C for
0 min. Nonadherent insect cells were washed away,
nd binding between mutant CD46 molecules and Ed-
onston H was quantified with the enzyme substrate
-nitrophenylgalactoside (ONPG), as shown in Fig. 2. The
esults with the mutant CD46 molecules were compared
ith binding obtained with normal CD46. Each experi-
ent was performed three separate times in triplicate,
nd values were expressed as standard deviations from
he mean. We considered only major decreases in bind-
ng to H protein as being relevant.
Mutation of hydrophobic residues at the amino-termi-
us of SCRI appeared to have very little effect on the
inding of CD46 to measles virus H protein; however,
ubstitution of tyrosine at amino acid 54 to serine (Y54S)
ed to a 30% reduction in binding, and mutations of
yrosine at amino acid 68 (Y68S) and phenylalanine at
mino acid 69 (F69S) led to more substantial inhibition,
anging between 40% and 50% (Fig. 2A). As we expected,
utations of Y62S and W86S abolished expression of
D46 molecule on the cell surface, and OST-7 cells
ontaining these mutant proteins did not bind to the H
rotein (Fig. 2A). On the other hand, mutation of the
ydrophobic residues in the SCRII domain produced
uch more dramatic inhibition without affecting expres-
ion of mutant CD46 on the cell surface. Substitution of
101, I102, V117, M123, F125, and W150 to serine com-
letely abolished binding to measles H protein. In addi-
ion, mutation of Y131S and L139S produced a moderate
0% reduction in binding, whereas the mutation L133S
roduced 60% less binding (Fig. 2B). We and others have
reviously shown that when R103 and D104 residues of
D46 were mutated to alanine, a significant inhibition of
inding was also evident (Hsu et al., 1997; Buchholz et
l., 1997), suggesting that this region of SCRII might be
rucial for interaction with H protein.
apping antigenic epitopes on CD46 that are
ecognized by monoclonal antibodies that inhibit
inding to measles virus H protein
To further define specific regions of CD46 that are
nvolved in binding to H, we examined the ability of five
or the majority of mutants, the non-normalized fluorescence values w
urface expression of the mutant proteins. After normalization, the sign
as computed as a geometric mean. The reactivity of the different mono
hat of wild-type CD46. (C) Western blot analysis with the monoclonal
olecules in mouse OST-7 cells infected with recombinant vaccinia viru
n recognition by J4/48 and E4.3 are demonstrated. Molecular mass pro
L46/47S, Y53S, Y54S, V60S, and Y62S) helps to define the antigenic e
igrating with a molecular mass of 60 kDa is also evident. Expression o
ith polyclonal CD46 antibodies.ifferent CD46-specific monoclonal antibodies to inhibit
he interaction between CD46 and measles H protein.
onoclonal antibodies J4/48, E4.3, and B97 were previ-
usly shown to interact with the SCRI domain, whereas
75 was mapped to the SCRII consensus region (Do¨rig,
993; Iwata et al., 1995; Hsu et al., 1997; Buchholz et al.,
997). In addition, the 122-2 monoclonal antibody was
hown to bind SCRII using CD46 deletion mutants pre-
iously generated in our laboratory (data not shown).
uman 143B TK2 osteosarcoma cells expressing CD46
ere incubated with a 1:20 dilution of the monoclonal
ntibody, Sf9 insect cells with H on their surface were
dded, and nonadherent cells were washed away. Bind-
ng of insect cells expressing measles virus H protein
nd b-galactosidase was quantified by measuring ONPG
ydrolysis in a colorimetric assay, and the results are
resented in Fig. 2C. Of the SCRI-specific monoclonal
ntibodies, E4.3 appeared to inhibit binding by 40%, B97
ntibody dramatically reduced binding by 80%, and J4/48
nly slightly blocked binding (,12%). On the other hand,
oth SCRII-specific antibodies, M75 and 122-2, appeared
o inhibit binding very efficiently (.70%).
Antigenic epitopes recognized by the five different
onoclonal antibodies were mapped using either immu-
oblotting or fluorescence cytometry analysis. In the first
pproach, OST-7 cells were infected with the different
ecombinant vaccinia viruses expressing CD46 mutants,
ell lysates were prepared, and proteins were subjected
o SDS–PAGE and transferred to nitrocellulose mem-
ranes. The immunoblot was recognized by both J4/48
nd E4.3 antibodies but failed to react with B97, M75, or
22-2 monoclonals. This result indicated that J4/48 and
4.3 recognized either linear or partially renatured
pitopes from proteins on the nitrocellulose. The analy-
is of eight representative CD46 mutants is shown in Fig.
C. Expression of CD46 mutant proteins in all OST-7 cell
ysates was verified using a polyclonal CD46 antibody. A
onspecific protein band that migrated with a molecular
ass of 60 kDa was recognized by the two monoclonal
ntibodies. Both E4.3 and J4/48 antibodies appeared to
ave very similar epitopes involving residues at position
6/37 and between amino acids 46 and 62. The E4.3
ntibody failed to recognize E36A/E37A, L46S/I47S, and
62S mutants and had reduced recognition for Y53S,
54S, and V60S. Similarly, J4/48 antibody failed to recog-
ize E36A/E37A, Y53S, and Y54S mutants and had re-
uced recognition for L46S/I47S, V60S, Y62S, and W86S
ithin 10% the levels found for wild-type CD46, indicating efficient cell
to a specific monoclonal antibody reacting with the mutagenized SCR
antibodies with the mutagenized portions of CD46 was compared with
ies J4/48 and E4.3 were used to confirm expression of mutant CD46
is example, the effects of eight individual mutations in SCRI and SCRII
ndards (Da) are located to the left of the blot. The absence of reactivity
recognized by J4/48 and E4.3 antibodies. A nonspecific protein band
tant CD46 proteins in OST-7 cells was verified by probing immunoblotsere w
al due
clonal
antibod
s. In th
tein sta
pitope
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318 HSU ET AL.TABLE 1
Site-Specific Mutagenesis of CD46 SCRI Domain, Cell Surface
xpression, and Reactivity of CD46 Mutant Proteins with Specific
ntibodies
Mutationa
Surface
expressionb
Reactivity with monoclonal
antibody
J4/48c E4.3c B97d
D46 C2 111 111 111 111
36A/E37A 111 2 2 111
41S 111 111 111 111
42A 111 111 1 111
44S 111 111 111 111
45A 111 111 1 111
46S/I47S 111 11 2 1
49A/K51A 111 2 2 111
53S 111 2 1 111
54S 111 2 1 111
55A 111 111 1 111
56S 111 111 111 111
58A/R59A 111 2 1 2
60S 111 1 11 111
61A/K63A 111 111 111 2
62S 2 1 2 2
65A/K66A 111 111 111 111
68S 111 111 111 111
69S 111 111 111 111
70S 111 111 111 1
71S 111 111 111 111
74S 111 111 111 111
77A 111 111 111 111
79S 111 111 111 111
81A/R82A 111 111 111 111
83A 111 111 111 111
84A 111 111 111 111
86S 2 1 111 2
87S 111 111 111 111
89S 111 111 111 111
91A/D92A 111 111 111 111
a The CD46 molecule (isotype C2) was subjected to site-specific mu-
agenesis as described previously. The position of the mutation is indi-
ated by the amino acid residue numbered from the N-terminus of the
olypeptide and includes the signal peptide before post-translational
leavage. The letter to the left of the number indicates the original amino
cid, and the letter to the right indicates the change.
b The mean fluorescence of CD46 mutant proteins that were expressed on
he surface of mouse OST-7 cells was determined by FACS analysis with
D46 SCRII specific monoclonal antibody (M75). Analysis was performed
wice with an error of 615%. The surface expression of each mutant is
ompared directly with the wild-type CD46. The percentage of standard
xpression is indicated as follows: 2 (no surface expression), 1 (,30%
xpression), 11 (31–65% expression), and 111 (.66% expression).
c Reactivity of the mutant CD46 molecules with monoclonal antibodies
4/48 and E4.3 was determined by immunoblot analysis of proteins from a
utant CD46 recombinant vaccinia virus-infected cell lysate. 2, No band
ppeared on the blot; 1, presence of a faint band; and 111, the mono-
lonal antibody recognized the mutant CD46 protein.
d Reactivity of the mutant CD46 molecules with monoclonal antibod-
es B97 was also determined by FACS analysis. The mean fluorescence
alues of different antibodies were normalized with wild-type CD46 as
escribed in Materials and Methods. The surface recognition of spe-
ific antibody to each mutant was compared with the reactivity with
ild-type CD46. The percentage of antibody recognition is indicated as
ollows: 2 (no antibody recognition), 1 (,30% recognition), 11 (31–
5% recognition), and 111 (.66% recognition).TABLE 2
Site-Specific Mutagenesis of CD46 SCRII Domain, Cell Surface
xpression, and Reactivity of CD46 Mutant Proteins with Specific
ntibodies
Mutationa
Surface
expressionb
Reactivity with
monoclonal
antibody c
M75 122-2
101S 111 111 2
102S 111 11 111
103A/D104A 111 2 2
106S 111 111 111
111S 111 111 111
114A 111 2 11
117S 111 111 111
118A 111 111 111
119S 111 111 111
121S 111 111 111
123S 111 1 1
124A 111 111 111
125S 111 2 2
126S 111 111 111
129A 111 111 111
131S 111 1 1
132S 111 111 111
133S 111 1 1
134S 111 111 111
136A 111 111 111
137A 111 111 111
138S 111 111 111
139S 111 1 1
140S 111 111 111
142A 111 111 111
143S 111 111 111
144A 111 111 111
147S 111 111 111
149S 111 111 111
150S 111 2 2
153A 111 111 111
156S 111 111 111
a The CD46 molecule (isotype C2) was subjected to site-specific
utagenesis as described previously. The position of the mutation
s indicated by the amino acid residue numbered from the N-
erminus of the polypeptide, and includes the signal peptide before
ost-translational cleavage. The letter to the left of the number
ndicates the original amino acid, and the letter to the right indicates
he change.
b The mean fluorescence of CD46 mutant proteins that were
xpressed on the surface of mouse OST-7 cells was determined by
ACS analysis with CD46 SCRI specific monoclonal antibody (J4/48).
nalysis was performed twice with an error of 615%. The surface
xpression of each mutant is compared directly with the wild-type
D46. The percentage of standard expression is indicated as fol-
ows: 2 (no surface expression), 1 (,30% expression), 11 (31–65%
xpression), and 111 (.66% expression).
c Reactivity of the mutant CD46 molecules with monoclonal anti-
odies M75 and 122-2 was also determined by FACS analysis.
he mean fluorescence values of different antibodies were normal-
zed with wild-type CD46. The surface recognition of specific anti-
ody to each mutant was compared directly with the recognition of
4/48 antibody to that mutant. The percentage of antibody recogni-
ion is indicated as follows: 2 (no antibody recognition), 1 (,30%
ecognition), 11 (31–65% recognition), and 111 (.66% recogni-
ion).
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319INTERACTION OF CD46 AND MEASLES VIRUSutants. Although both of these antibodies have very
imilar antigenic epitopes, these reagents do not equally
nhibit interaction between CD46 and H. This may be due
o differences in the binding affinity of these two antibod-
es with their corresponding epitopes.
Unlike J4/48 and E4.3, monoclonal antibodies B97,
75, and 122-2 did not recognize CD46 on immunoblots
nd appeared to require native epitopes for interaction.
e therefore used a second approach based on fluores-
ence cytometry to map the antigenic epitopes for these
ntibodies. Vaccinia virus recombinants expressing mu-
ated CD46 mutant molecules were used to infect OST-7
ells, which were subsequently analyzed for reactivity
ith B97, M75, and 122-2 antibodies by fluorescence
ytometry with M75 and compared with the immune
ecognition of normal CD46. Fluorescence from a stan-
ard monoclonal (either J4/48 or 122-2) reacting with the
onmutagenized SCR was first normalized to the same
evel of fluorescence as from wild-type CD46. In most
ases, non-normalized values were already within 10% of
ach other. The obvious exception was when the muta-
ion affected surface expression of CD46. After normal-
zation, the signal due to a specific monoclonal antibody
eacting with the mutagenized SCR was compared with
hat from the wild-type SCR and expressed as a percent-
ge. A representative analysis is shown in Fig. 1B, and
he results of all the mutations are summarized in Tables
and 2. B97 antibody reacted weakly with CD46 mole-
ules containing the L46/I47 and Y70S mutations. As
xpected, it did not react with the two mutants (Y62S and
86S) that were not expressed on the cell surface. The
ntibody 122-2 failed to recognize CD46 molecules con-
aining Y101S, F125S, or W150S mutations and had re-
uced recognition for proteins with the changes M123S,
131S, L133S, and L139S. The M75 antibody had a sim-
lar recognition profile; it also did not recognize proteins
ith F125S and W150S mutations and exhibited reduced
inding to molecules containing I102S, M123S, Y131S,
133S, and L139S changes. Our laboratory and another
ave previously shown that M75 fails to recognize CD46
olecules where polar amino acids between R103 and
114 were replaced with alanine (Hsu et al., 1997, Buch-
olz et al., 1997). The significance of the epitope mapped
y the W150S mutation is not clear, but this mutation also
nhibits the binding of CD46 to H. We believe that the
egion containing Y101, R103, N114, and F125 must be
ritical for the interaction between CD46 and H. It seems
mportant to note that the residues implicated as forming
xis of the histogram, and the various CD46 mutations that were
ssayed are presented on the x axis. (A) Mutations in the SCRI domain
hat were assayed. (B) Mutations in the SCRII domain that were as-
ayed. (C) Effects of SCRI-specific monoclonal antibodies (E4.3, J4/48,
nd B97) and SCRII-specific monoclonal antibodies (122-2 and M75) on
inding of normal CD46 to measles virus H protein. All results are
xpressed as mean values of three assays, and standard deviations
re indicated.FIG. 2. Interaction between mutant CD46 molecules and measles H
Edmonston strain) protein effects of monoclonal antibodies (E4.4,
4/48, B97, 122-2, M75) on binding. Mutant CD46 molecules were
xpressed on the surface of mouse OST-7 cells using a recombinant
accinia virus expression system, and measles virus H protein was
xpressed on the surface of insect Sf9 cells using recombinant bacu-
oviruses that also contained the b-galactosidase gene. OST-7 and Sf9
ells were incubated for 30 min, nonadherent Sf9 cells were washed
way, and binding was quantified with the ONPG colorimetric assay.
inding relative to that of normal human CD46 is represented on the y
320 HSU ET AL.
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322 HSU ET AL.ntigenic epitopes for both M75 and 122-2 antibodies
oincided with regions in SCRII in which mutations pro-
uced the most drastic effects.
olecular model showing amino acid residues on
D46 that seem to be important in binding to
easles virus H protein
The SCRI and SCRII domains of CD46 have previously
een modeled based on the similar SCR15 and SCR16
omains of factor H, another member of the RCA family
Barlow et al., 1993; Mumenthaler et al., 1997; Buchholz
t al., 1997; Manchester et al., 1997). Using the RasMol
.6 Molecular Graphics Visualisation Program and the
oordinates for the CD46 SCRI and II domains from the
ypothetical model, which were provided by Drs. Roberto
attaneo and Werner Braun (Mumenthaler et al., 1997),
e were able to visualize the locations of different amino
cids contributing to the antigenic epitopes recognized
y the inhibitory monoclonal antibodies (Fig. 3). We also
apped the regions where site-directed mutations
ielded reduced binding between CD46 and H (Fig. 4).
or the most part, all mutations that correlate with the
eduction or abolition of binding are located on the same
ace of the model (Figs. 3A and 4A). Hydrophobic amino
cids involved in forming the antigenic epitopes for E4.3
nd J4/48 antibodies (L46, I47, Y53, Y54, V60) are clus-
ered together in Fig. 3A, top left. This region lies directly
bove E45 and adjacent to the 58E/R59, residues that
ere previously implicated in binding studies after mu-
agenesis to alanine (Hsu et al., 1997). The antibody E4.3
as also been shown, through site-specific mutagenesis,
o interact with E36, E37, E42, E45, K49, K51, E55, E58,
nd R59 (Hsu et al., 1997; Buchholz et al., 1997), which lie
irectly behind these hydrophobic residues (Fig. 3B). The
onoclonal antibody J4/48 was determined by our labo-
atory to have a similar recognition pattern (Table 1).
hus the antigenic recognition site for E4.3 and J4/48
ppears to straddle the top portion of SCRI. On the other
and, B97 antibodies appear to interact with another
artially overlapping region composed of the hydropho-
ic amino acids L46, I47, and Y70 and the polar amino
cids R59, D61, and K63. This antibody appears to inter-
ct with the front face of SCRI (Fig. 3A). Taken together,
FIG. 3. Antigenic epitopes on SCRI and SCRII that are recognized b
protein and CD46. Assays were performed as described in Tables 1
he space-filled option of the RasMol 2.6 Molecular Graphic Visualizat
hat react with all three (J4/48, E4.3, and B97) antibodies; green residue
ellow residues correspond to amino acids interacting with B97. In the S
hereas the red residues reacted only with the 122-2 monoclonal antib
B) An opposite rear view of the model (180-degree rotation).
FIG. 4. Representation of residues implicated in binding of the meas
CRI and II domains were visualized using the space-filled option of th
range residues represent hydrophilic amino acids that reduce binding
cids that affect binding when mutated to serine. In the SCRII domain
utated to alanine, and red residues are the hydrophobic amino acids t
esidues most sensitive to change are situated. (B) A rear view of thehe monoclonal antibody inhibition and site-specific mu-
agenesis results indicate that R59 is a key residue in
CRI–H protein interaction because it is common to all
pitopes. Residues Y62 and W86 appear to be internal
esidues that constitute the hydrophobic core of SCRI
nd could act to hold together the domain. Therefore,
utation of these two amino acids to serine could result
n misfolding and account for the loss in CD46 surface
xpression (Figs. 2A and 2B). Amino acids Y68 and F69
re located below the predicted epitopes for E4.3, J4/48,
nd B97 antibodies, but they may play some role in H
rotein interaction because changes at these positions
o yield 50–55% inhibition in binding. However, muta-
ions at Y101, I102, Y117, M123, and F125 and W150 in the
CRII domain produce dramatic and almost total inhibi-
ion of binding. Examination of the model reveals that
123, F125, and W150 are buried residues, and they may
elp retain the active conformation of SCRII. Changes at
hese residues may result in global distortion of SCRII
nd thereby affect both receptor binding and monoclonal
ntibody recognition. Antigenic epitopes for the M75 and
22-2 monoclonal antibodies appear to contain Y101,
102, R103, D104, and N114 residues. Changes at Y131,
133, and L139 also reduce recognition by M75 and
22-2, but again these residues appear to be buried, and
utation of these residues probably affects the antigenic
pitope through disruption of the overall SCRII confor-
ation. SCRII residues implicated in binding to H all lie
n the front side of the model (Fig. 3A). R103, D104, and
114, also situated near the Y101 and I102, have also
reviously been shown to affect binding (Hsu et al.,
997). The glycosylation site at N114 lies opposite to
hese residues, and although it was previously shown to
e important for binding, mutations of this residue inhib-
ted interaction between CD46 and H by only 45% (Hsu et
l., 1997). The carbohydrate associated with this region
ay serve as a spacer to orient SCRI and SCRII relative
o each other rather than being actively involved in bind-
ng to H protein. (Fig. 3A). The interpretation of our CD46
utagenesis results must still be approached with some
aution because the changes may not always produce
ocalized effects. Instead, they may cause alterations in
he global structure of the molecule. An exact assign-
fic monoclonal antibodies that inhibit binding between measles virus
olecular models of CD46 SCRI and II domains were visualized using
gram. In the SCRI domain, orange residues represent antigenic sites
sent antigenic sites recognized by both J4/48 and E4.3 antibodies; and
main, blue residues are recognized by both 122-2 and M75 antibodies,
) The face of the model on which most antigenic residues are located.
s H protein to CD46 SCRI and II domains. Molecular models of CD46
ol 2.6 Molecular Graphic Visualization Program. In the SCRI domain,
utated to alanine, whereas green residues are the hydrophobic amino
esidues represent hydrophilic amino acids that reduce binding when
ct binding when mutated to serine. (A) The face of the model on which
(180-degree rotation) is shown.y speci
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323INTERACTION OF CD46 AND MEASLES VIRUSent of residues directly involved in receptor binding
waits the three-dimensional structural determination of
D46 and the measles virus H protein.
DISCUSSION
A similar approach involving site-specific mutagenesis
nd the mapping of inhibitory monoclonal antibody
pitopes has previously been used dissect the regions of
D4 (amino acids 39–59) that interact with the gp120
nvelope protein of HIV-1 (Arthos et al., 1989; Ashkenazai
t al., 1990; Bowman et al., 1990; Brodsky et al., 1990;
layton et al., 1988; Jameson et al., 1988; Mizukami et al.,
988; Peterson and Seed, 1988; Sattenau et al., 1986; Tsui
t al., 1992). Residues F43 and R59 of CD4 were found to
e critical for interaction with D368, E370, and W427 of
p120 through these mutagenesis studies. These results
ave recently been borne out through crystallographic
ata obtained from a complex of the two terminal do-
ains of CD4 and gp120 (Kwong et al., 1998). CD4 res-
dues (spanning amino acids 25–64) insert into a depres-
ion consisting of 26 amino acids derived from six dif-
erent segments of gp120. Synthetic peptides were also
sed by workers at other laboratories in attempts to map
inding regions on CD4, but these experiments led to
ontradictory results (Jameson et al., 1988; Levy, 1994;
ifson et al., 1988; Repke et al., 1992; Zhang et al., 1997).
nitially we also attempted to perform peptide inhibition
tudies with measles virus and CD46 by using 25-amino-
cid peptides derived from all regions of SCR1 and
CR2, but in our hands, peptides at concentrations as
igh as 200 mM had no effect in Sf9-H binding and
easles virus infectivity assays. We presumed that the
nteraction of measles virus hemagglutinin with CD46
epended more on conformational epitopes than on lin-
ar peptide regions. Our results using mutagenesis and
nhibitory monoclonal antibodies implicate E45, 58E/R59,
68, F69, Y101, I102, R103, D104, N114, and Y117 in the
inding of SCRI/SCRII domains of CD46 to measles virus
emagglutinin. The carbohydrate attached to N114 prob-
bly does not participate directly in binding but may
erve to correctly orient SCRI with respect to SCRII and
ay act to favor binding indirectly. Three-dimensional
nalysis using x-ray crystallography and NMR should
ventually complement these studies.
Two other groups have attempted to map the regions
f CD46 that bind to measles virus H protein. One labo-
atory used a series of 26 overlapping peptides spanning
CR1 and SCR2 to inhibit measles virus infections
Manchester et al., 1996). These investigators found that
eptides derived from Y70–V89 in SCR1 and E118–E137
n SCR2 could inhibit infections and virus-mediated hem-
gglutination of monkey red blood cells at concentra-
ions of 100 mM. In addition, these researchers ex-
hanged the peptide regions implicated in binding with
nalogous stretches of amino acids from CD55, another
ember of the RCA family. They found that the CD55olypeptide regions introduced into CD46 blocked viral
nfections. The opposite experiment by which putative
D46 binding regions were introduced into CD55 was
ot reported. However, we previously found that CD46
id not tolerate multiple amino acid changes in almost all
egions of SCR1 and SCR2 (Hsu et al., 1997), so these
esults with chimeric CD55–CD46 should be interpreted
ith caution. The results of this laboratory imply that
easles virus H protein interacts with linear peptide
omains on SCR1 and SCR2 and led these investigators
o propose a model for CD46 based on a known three-
imensional structure of the SCRs from factor H (Barlow
t al., 1993).
Researchers at another laboratory used an approach
imilar to ours to map the H protein binding domains of
D46 (Buchholz et al., 1997). A series of 40 mutations
ere introduced into the SCR1 and SCR2 domains that
hanged mainly polar amino acids to alanine. The effect
f these CD46 changes on binding to soluble recombi-
ant H protein was measured by FACS analysis. This
ethod proves to be less sensitive than our binding
ssay, which amplifies the H binding signal through
-galactosidase, which is also expressed in the insect
ells. In addition, the 40 mutations were used by the
ther laboratory workers to map the binding sites of 11
onoclonal antibodies that block the interaction of H
rotein with CD46. The mutations E45A, K63A, P73A, and
104A reduced binding to H protein. It was surprising
hat these single amino acid mutations did not have a
reater effect on binding to soluble H, but this could be
elated to the sensitivity of their assay. In addition, four of
he monoclonal antibodies tested, E4.3, J4/48, B97, and
75, were the same as those tested in our laboratory.
or the most part, these monoclonals mapped to the
ame regions of CD46 as presented in our report. As we
ound, the B97 and M75 antibodies were highly efficient
n blocking H protein attachment to CHO-CD46 cells and
4.3 and J4-48 were less effective in blocking binding.
97 mapped to R59, D61, and K63 in their hands and
8ER59, D61, and K63 in our experiments. M75 mapped
o R103 and Q124 in the other group’s experiments and to
102, 103RD104, N114, and M123 in our experiments. E4.3
ntibody reacted with E36 and E37 in both studies but
lso appears to involve L46/I47 and K49/K51. Slight dif-
erences in mapping the epitopes of these monoclonal
ntibodies may be related to the fact that we used
mmunoblots as well as FACS analysis to monitor the
hange of reactivity of antibodies toward the mutant
roteins. We concluded that J4-48 antibody interacted
ith SCR1, based on previous publications (Buchholz et
l., 1997; Iwata et al., 1995; Seya et al., 1995), and that its
pitope consisted of residues 49KK51, Y53, Y54, 58ER59,
nd V60.
Our results indicate that E45, Y54, 58E/R59, Y68, F69,
101, I102, R103, D104, and Y117 seem to be critical
esidues for the binding of CD46 to measles virus H
rotein. Hydrophilic interaction with R59 in SCR1, as
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324 HSU ET AL.hown in our previous publication (Hsu et al., 1997), and
ydrophobic bonding with residues Y68, F69, Y101, I102,
nd Y117 seem to be especially important. Other hydro-
hobic residues such as Y62, W86, M123, F125, L133,
nd W150 appear to be buried, and substitutions of these
mino acids probably distort the overall conformation of
CR1 and SCR2 and indirectly inhibit binding of H to
D46. Amino acids implicated in binding seem to lie on
ne face of SCR1 and SCR2. Our structural interpreta-
ions concerning the role of individual amino acids in
inding is based on the most likely model structure
erived by superimposing the amino acids of CD46
CR1/SCR2 on the related three-dimensional structure of
actor H domains 15/16 (Mumenthaler et al., 1997). The
nterpretation of our data is also made with the under-
tanding that individual amino acid changes could distort
he global structure of CD46 and indirectly affect its
inding to H protein. A similar modeling approach has
een applied to the four SCR domains of the related
D55 molecule (Kuttner-Kondo et al., 1996). Although the
onformations of SCR1 and SCR2 are generally predict-
ble, uncertainty is derived by possible rotation about the
inge region between the two domains. Other viruses
uch as Epstein–Barr virus, Coxsackie viruses, and
choviruses also bind to members of the RCA comple-
ent regulatory family (Moore et al., 1981; Clarkson et al.,
995; Dimock et al., 1996). In each of these cases, the
irus appears to react with two or three domains of their
eceptors. Epstein–Barr virus reacts with the two termi-
al domains of CD21m and coxsackie viruses and echo-
iruses bind to SCRII–IV of CD55. Confirmation and a
ore precise assignment of the residues involved in
D46-H binding will depend on the elucidation of three-
imensional structures of CD46 and the measles virus H
rotein through NMR and x-ray crystallography studies,
hich are under way in our laboratory.
MATERIALS AND METHODS
ell lines and virus
HuTK-143B cells and mouse OST-7 cells, which ex-
ressed T7 polymerase, were used in isolating and ex-
ressing vaccinia virus recombinants, respectively. They
ere purchased from American Type Culture Collection
Rockville, MD). These cells were cultured in Dulbecco’s
inimal essential medium containing 10% FCS as previ-
usly described (Hsu et al., 1997). Sf9 insect cells were
btained from InVitrogen (San Diego, CA) and cultured in
race’s medium containing 10% FCS. The Montefiore 89
solate of measles virus was obtained from M. Sidhu at
yeth-Lederle Pediatric Vaccine Laboratories, and the
dmonston laboratory strain of measles virus, which had
een adapted to Vero cells, originally came from E.
orrby (Karolinska Institute, Stockholm, Sweden).ntibodies
The monoclonal antibody E4.3 (specific for SCR1) was
urchased from Bio/Can Scientific (Mississauga, Cana-
a). M75 (specific for SR2) came from Seikugaku (Tokyo,
apan). J4-48 was supplied by Serotec (Kidlington, Ox-
ord, UK). 122-2 (specific for SCR2) was purchased from
iodesign International (Kennebunk, ME). B97 (specific
or SCR1) came from the laboratory of J. Schneider-
chaullies and V. ter Meulen (Universitat Wu¨rzburg).
utagenesis of CD46 coding sequences and DNA
equencing
SCR1 and SCR2 domains were altered with point mu-
ations using gel-purified oligonucleotides consisting of
0–40 nucleotides. Mutations were introduced into the
D46 molecule by using the QuickChange site-directed
utagenesis kit from Stratagene. The CD46-coding re-
ion (isotype C2) was cloned into PCR-Script Amp SK(1)
lasmid, denatured, and annealed with two complemen-
ary oligonucleotides containing the desired mutation.
he mutagenized DNA strands were extended with Pfu
olymerase, the methylated nonmutated parental DNA
emplate was digested with DpnI, and the mutated plas-
id was used to transform XL2-Blue ultracompetent
ells. Mutant plasmids were isolated, and the CD46
nserts were completely sequenced. The mutagenized
D46 coding regions were excised from the PCR-Script
lasmid after digestion with BspHI (59 end) and BglII (39
nd) and ligated into the vaccinia vector pTM1 (contain-
ng the T7 promoter), which had been digested with the
ompatible restriction enzymes NcoI and BamHI. Vac-
inia virus recombinants were prepared and titered by
laque assays as previously described using HuTK2
43B cells and bromodeoxyuridine selection (Earl et al.,
995). CD46 mutants were expressed in mouse OST-7
ells that contained the T7 polymerase and protein syn-
hesis, and surface expression was monitored by West-
rn immunoblotting and FACS scan analysis.
inding assays performed between mutant CD46
olecules and insect cells expressing Edmonston
easles virus H protein
We previously developed a binding assay that mea-
ured the interaction between CD46 molecules ex-
ressed in mouse fibroblasts and Sf9 insect cells ex-
ressing both the measles virus H protein and b-galac-
osidase (Hsu et al., 1997, 1998). Mutant CD46 coding
equences were cloned into the pTM1 vaccinia expres-
ion vector, which uses the T7 promoter to direct tran-
cription of the foreign gene. Recombinant vaccinia virus
as prepared as previously described (Earl et al., 1995),
nd mutant CD46 molecules were expressed in mouse
ST7 cells, which contain the T7 polymerase. Sf9 insect
ells were infected for 48 h with a recombinant baculo-
irus (Vialard and Richardson, 1990) that had been gen-
e
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325INTERACTION OF CD46 AND MEASLES VIRUSrated with the BlueBac2 expression vector (InVitrogen)
Richardson et al., 1992; Lalumie´re and Richardson,
995) and synthesized both the measles virus H protein
nd b-galactosidase. The insect cells were colored blue
y adding Bluogal (GIBCO BRL, Grand Island, NY) at 36-h
nfection from a stock solution (50 mg/ml in dimethylfor-
amide) to give a 0.05% (w/v) final concentration. Infec-
ions with recombinant vaccinia virus were allowed to
roceed for 12 h; Sf9 insect cells expressing the measles
protein and b-galactosidase were incubated for 30 min
ith the vaccinia-infected mouse OST7 cells in the pres-
nce of PBS containing 5% FCS. Nonadsorbed insect
ells were eluted by washing the mouse cells twice with
BS. Binding in 25-cm2 tissue culture flasks could be
uantified visually under the microscope or quantitatively
y the hydrolysis of ONPG using a b-galactosidase as-
ay kit (Stratagene, La Jolla, CA). Cells were lysed in 0.5
l of 100 mM sodium phosphate buffer (pH 7.5) contain-
ng 0.2% Triton X-100 and 1% Nonidet P-40. Aliquots of
ysate (50 ml) were added to a 96-well microtitration
late, and freshly prepared buffer (100 mM sodium phos-
hate, 10 mM KCl, 1 mM MgSO4, 50 mM b-mercapto-
thanol, pH7 .5) was mixed with each aliquot to give a
inal volume of 160 ml. A 50-ml volume of ONPG solution
4 mg/ml in 100 mM sodium phosphate, pH 7.5) was
dded to each well and incubated at 37o until a yellow
olor was evident after ;30 min. The reaction was ter-
inated by the addition of 90 ml of 1 M Na2CO3, and color
ntensity was measured at 420 nm with a SpectraMax
50 ELISA plate reader purchased from Molecular De-
ices (Sunnyvale, CA). Results were linear over time for
n absorbance range of 0.1–1 A420 unit.
luorescence cytometry of CD46 mutant proteins
Mouse OST7 cells (2 3 106 cells) that expressed
utant forms of CD46 were suspended in 1 ml of Cell
issociation Buffer (Sigma Chemical Co., St. Louis, MO)
nd washed twice by centrifugation with FACS buffer.
ells were resuspended in 100 ml of the same buffer
ontaining a 1:100 dilution of either nonimmune antibody
r a specific monoclonal antibody (E4.3, J4-48, M75,
22-2, or B97) for 1 h on ice. After the incubation, cells
ere washed twice with 3 ml of FACS buffer by centrif-
gation at 1500g for 5 min. The cells were resuspended
n 100 ml of the same buffer containing a 1:100 dilution of
ITC-labeled anti-rabbit IgG (H 1 L) for 1 h on ice. After
ashing twice with the 3 ml of FACS buffer, the blood
ells were suspended in 0.5 ml of FACS buffer and were
ubsequently analyzed on a Becton Dickinson analyzer
quipped with a 15-mW argon laser at 488 nm. The data
ere collected and analyzed using CellQuest software.
he final pellet was suspended in 100 ml of FACS buffer
efore analysis by fluorescence cytometry. The reactivity
f the different monoclonal antibodies with the mu-
agenized portions of CD46 was compared with reactivity
ith the wild-type molecule. Fluorescence from a stan-ard monoclonal (either J4/48 or 122-2) reacting with the
onmutagenized SCR was first normalized to the same
evel of fluorescence as from wild-type CD46. In most
ases, non-normalized values were already within 10% of
ach other. The obvious exception was when the muta-
ion affected surface expression of CD46. After normal-
zation, the signal due to a specific monoclonal antibody
eacting with the mutagenized SCR was computed as a
eometric mean. The mean fluorescence due to a mono-
lonal antibody reacting with mutant CD46 was com-
ared with that from the wild-type CD46 and expressed
s a percentage.
olecular modeling
Changes in CD46 that reduced binding or recognition
y inhibitory monoclonal antibodies were mapped on a
tructural model of the SCRI and SCRII domains, which
as provided by Dr. R. Cattaneo (University of Zu¨rich)
nd Dr. W. Braun (University of Texas Medical Branch,
alveston, TX) (Buchholz et al., 1997). This model was a
imulation performed with the DIAMOD and FANTOM
odeling programs based on the related structure of
actor H (Barlow et al., 1993; Mumenthaler et al., 1997).
odels were viewed with the RasMol 2.6 Molecular
raphics Visualization Program (Dr. R. Sayle, Glaxo Well-
ome, UK). Four possible configurations were reported,
ut only one model (M1) is consistent with the observa-
ions of both of our laboratories.
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